Falsified Medicines - Bridging the Gap between Business and Public Health

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Falsified Medicines - Bridging the Gap between Business and Public Health. / Borup, Rasmus; Traulsen, Janine Marie.

In: Pharmacy, Vol. 4, No. 2, 28.03.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Borup, R & Traulsen, JM 2016, 'Falsified Medicines - Bridging the Gap between Business and Public Health', Pharmacy, vol. 4, no. 2.

APA

Borup, R., & Traulsen, J. M. (2016). Falsified Medicines - Bridging the Gap between Business and Public Health. Pharmacy, 4(2).

Vancouver

Borup R, Traulsen JM. Falsified Medicines - Bridging the Gap between Business and Public Health. Pharmacy. 2016 Mar 28;4(2).

Author

Borup, Rasmus ; Traulsen, Janine Marie. / Falsified Medicines - Bridging the Gap between Business and Public Health. In: Pharmacy. 2016 ; Vol. 4, No. 2.

Bibtex

@article{2575fad1b7f44feea50a7c255232a264,
title = "Falsified Medicines - Bridging the Gap between Business and Public Health",
abstract = "The pharmaceutical industry is one of the most regulated industries in the world. While legislation is necessary to protect patients, too much legislation is said to hamper innovation and increase medicine prices. Using qualitative methods such as interviews and document analysis, we investigated the role of private stakeholders in the EU policymakers’ decision to initiate legislation to combat falsified medicines in 2008. Our results show that the pharmaceutical industry, brand owners in particular, were strong proponents of legislation to combat falsified medicines. Their support was not fueled by fear that falsified medicines would harm patients or their own business, but rather because legislative action in this area would advance policies that benefit their businesses objectives. The brand owners framed the issue to policymakers as best to support their business objectives. In general, supply chain actors lobbied for stricter requirements in order to challenge competitors. In the end, the Falsified Medicines Directive may have suffered from company influence not by addressing the primary problem of falsified medicines, but rather by creating additional legislation that benefits the supply chain actors.",
author = "Rasmus Borup and Traulsen, {Janine Marie}",
year = "2016",
month = "3",
day = "28",
language = "English",
volume = "4",
journal = "Pharmacy",
issn = "2226-4787",
publisher = "M D P I AG",
number = "2",

}

RIS

TY - JOUR

T1 - Falsified Medicines - Bridging the Gap between Business and Public Health

AU - Borup, Rasmus

AU - Traulsen, Janine Marie

PY - 2016/3/28

Y1 - 2016/3/28

N2 - The pharmaceutical industry is one of the most regulated industries in the world. While legislation is necessary to protect patients, too much legislation is said to hamper innovation and increase medicine prices. Using qualitative methods such as interviews and document analysis, we investigated the role of private stakeholders in the EU policymakers’ decision to initiate legislation to combat falsified medicines in 2008. Our results show that the pharmaceutical industry, brand owners in particular, were strong proponents of legislation to combat falsified medicines. Their support was not fueled by fear that falsified medicines would harm patients or their own business, but rather because legislative action in this area would advance policies that benefit their businesses objectives. The brand owners framed the issue to policymakers as best to support their business objectives. In general, supply chain actors lobbied for stricter requirements in order to challenge competitors. In the end, the Falsified Medicines Directive may have suffered from company influence not by addressing the primary problem of falsified medicines, but rather by creating additional legislation that benefits the supply chain actors.

AB - The pharmaceutical industry is one of the most regulated industries in the world. While legislation is necessary to protect patients, too much legislation is said to hamper innovation and increase medicine prices. Using qualitative methods such as interviews and document analysis, we investigated the role of private stakeholders in the EU policymakers’ decision to initiate legislation to combat falsified medicines in 2008. Our results show that the pharmaceutical industry, brand owners in particular, were strong proponents of legislation to combat falsified medicines. Their support was not fueled by fear that falsified medicines would harm patients or their own business, but rather because legislative action in this area would advance policies that benefit their businesses objectives. The brand owners framed the issue to policymakers as best to support their business objectives. In general, supply chain actors lobbied for stricter requirements in order to challenge competitors. In the end, the Falsified Medicines Directive may have suffered from company influence not by addressing the primary problem of falsified medicines, but rather by creating additional legislation that benefits the supply chain actors.

M3 - Journal article

VL - 4

JO - Pharmacy

JF - Pharmacy

SN - 2226-4787

IS - 2

ER -

ID: 159423221